Cyclin-dependent kinases: Molecular switches controlling anergy and potential therapeutic targets for tolerance

Seminars in Immunology

Volumn 19, Issue 3, 2007, Pages 173-179

  Wells, Andrew D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anergy; Cell cycle; Cyclin dependent kinases; T lymphocyte; Tolerance

Indexed keywords

CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; FLAVOPIRIDOL; MITOGENIC AGENT; ROSCOVITINE;

AUTOIMMUNITY; CANCER; CD4+ T LYMPHOCYTE; CELL CYCLE; CLINICAL TRIAL; CLONAL ANERGY; GENETIC TRANSCRIPTION; GLOMERULOPATHY; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY POLYCYSTIC DISEASE; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PLEURISY; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 34249657416     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2007.02.009     Document Type: Review

References (65)

1. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., and Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166 (2001) 973-981
2. Rowell E.A., and Wells A.D. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. Crit Rev Immunol 26 (2006) 189-212
3. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2 (2003) S84-S95
4. Murphy K.M., and Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2 (2002) 933-944
5. Bird J.J., Brown D.R., Mullen A.C., Moskowitz N.H., Mahowald M.A., Sider J.R., et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 9 (1998) 229-237
6. Gett A.V., and Hodgkin P.D. Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. Proc Natl Acad Sci USA 95 (1998) 9488-9493
7. Gudmundsdottir H., Wells A.D., and Turka L.A. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 162 (1999) 5212-5223
8. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., and Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173 (1991) 721-730
9. Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., and Allison J.P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356 (1992) 607-609
10. Gimmi C.D., Freeman G.J., Gribben J.G., Gray G., and Nadler L.M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90 (1993) 6586-6590
11. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305-334
12. Boussiotis V.A., Barber D.L., Lee B.J., Gribben J.G., Freeman G.J., and Nadler L.M. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 184 (1996) 365-376
13. DeSilva D.R., Feeser W.S., Tancula E.J., and Scherle P.A. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways. J Exp Med 183 (1996) 2017-2023
14. Fields P.E., Gajewski T.F., and Fitch F.W. Blocked Ras activation in anergic CD4+ T cells. Science 271 (1996) 1276-1278
15. Li W., Whaley C.D., Mondino A., and Mueller D.L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271 (1996) 1272-1276
16. Sloan-Lancaster J., Steinberg T.H., and Allen P.M. Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 184 (1996) 1525-1530
17. Boussiotis V.A., Freeman G.J., Berezovskaya A., Barber D.L., and Nadler L.M. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 278 (1997) 124-128
18. Wells A.D., Walsh M.C., Sankaran D., and Turka L.A. T cell effector function and anergy avoidance are quantitatively linked to cell division. J Immunol 165 (2000) 2432-2443
19. Wells A.D., Liu Q.H., Hondowicz B., Zhang J., Turka L.A., and Freedman B.D. Regulation of T cell activation and tolerance by phospholipase cgamma-1-dependent integrin avidity modulation. J Immunol 170 (2003) 4127-4133
20. Telander D.G., Malvey E.N., and Mueller D.L. Evidence for repression of IL-2 gene activation in anergic T cells. J Immunol 162 (1999) 1460-1465
21. Kitagawa-Sakakida S., and Schwartz R.H. Multifactor cis-dominant negative regulation of IL-2 gene expression in anergized T cells. J Immunol 157 (1996) 2328-2339
22. Powell J.D., Lerner C.G., Ewoldt G.R., and Schwartz R.H. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 163 (1999) 6631-6639
23. Bruniquel D., and Schwartz R.H. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 4 (2003) 235-240
24. Thomas R.M., Gao L., and Wells A.D. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol 174 (2005) 4639-4646
25. Murayama A., Sakura K., Nakama M., Yasuzawa-Tanaka K., Fujita E., Tateishi Y., et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. Embo J 25 (2006) 1081-1092
26. Macian F., Garcia-Cozar F., Im S.H., Horton H.F., Byrne M.C., and Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109 (2002) 719-731
27. Mueller D.L. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5 (2004) 883-890
28. Powell J.D. The induction and maintenance of T cell anergy. Clin Immunol 120 (2006) 239-246
29. DeSilva D.R., Urdahl K.B., and Jenkins M.K. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 147 (1991) 3261-3267
30. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266 (1994) 1039-1042
31. Beverly B., Kang S.M., Lenardo M.J., and Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4 (1992) 661-671
32. Wells A.D., Gudmundsdottir H., and Turka L.A. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 100 (1997) 3173-3183
33. Wells A.D., Walsh M.C., Bluestone J.A., and Turka L.A. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 108 (2001) 895-903
34. Jackson S.K., DeLoose A., and Gilbert K.M. Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J Immunol 166 (2001) 952-958
35. Jackson S.K., DeLoose A., and Gilbert K.M. The ability of antigen, but not interleukin-2, to promote n-butyrate-induced T helper 1 cell anergy is associated with increased expression and altered association patterns of cyclin-dependent kinase inhibitors. Immunology 106 (2002) 486-495
36. Powell J.D., Lerner C.G., and Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 162 (1999) 2775-2784
37. Vanasek T.L., Khoruts A., Zell T., and Mueller D.L. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol 167 (2001) 5636-5644
38. Verdoodt B., Blazek T., Rauch P., Schuler G., Steinkasserer A., Lutz M.B., et al. The cyclin-dependent kinase inhibitors p27Kip1 and p21Cip1 are not essential in T cell anergy. Eur J Immunol 33 (2003) 3154-3163
39. Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6 (2000) 290-297
40. Harbour J.W., and Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14 (2000) 2393-2409
41. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994) 59-66
42. Rowell E.A., Walsh M.C., and Wells A.D. Opposing roles for the cyclin-dependent kinase inhibitor p27kip1 in the control of CD4+ T cell proliferation and effector function. J Immunol 174 (2005) 3359-3368
43. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
44. Li L., Iwamoto Y., Berezovskaya A., and Boussiotis V.A. A pathway regulated by cell cycle inhibitor p27(Kip1) and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 7 (2006) 1157-1165
45. Chen E., and Li C.C. Association of Cdk2/cyclin E and NF-kappa B complexes at G1/S phase. Biochem Biophys Res Commun 249 (1998) 728-734
46. Dynlacht B.D. Regulation of transcription by proteins that control the cell cycle. Nature 389 (1997) 149-152
47. Perkins N.D., Felzien L.K., Betts J.C., Leung K., Beach D.H., and Nabel G.J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275 (1997) 523-527
48. Matsuura I., Denissova N.G., Wang G., He D., Long J., and Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430 (2004) 226-231
49. Balomenos D., Martin-Caballero J., Garcia M.I., Prieto I., Flores J.M., Serrano M., et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 6 (2000) 171-176
50. Santiago-Raber M.L., Lawson B.R., Dummer W., Barnhouse M., Koundouris S., Wilson C.B., et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 167 (2001) 4067-4074
51. Lawson B.R., Baccala R., Song J., Croft M., Kono D.H., and Theofilopoulos A.N. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 199 (2004) 547-557
52. Rowell E.A., Wang L., Hancock W.W., and Wells A.D. The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade. J Immunol 177 (2006) 5169-5176
53. Wells A.D. T cell costimulatory pathways relevant to transplant rejection and tolerance. Transplantation Rev 16 (2002) 205
54. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
55. Kovalev G.I., Franklin D.S., Coffield V.M., Xiong Y., and Su L. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol 167 (2001) 3285-3292
56. Tourigny M.R., Ursini-Siegel J., Lee H., Toellner K.M., Cunningham A.F., Franklin D.S., et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity 17 (2002) 179-189
57. Huang X., Di Liberto M., Cunningham A.F., Kang L., Cheng S., Ely S., et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci USA 101 (2004) 17789-17794
58. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
59. Knockaert M., Greengard P., and Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23 (2002) 417-425
60. Senderowicz A.M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16 (2004) 670-678
61. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102 (2002) 463-468
62. Osuga H., Osuga S., Wang F., Fetni R., Hogan M.J., Slack R.S., et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci USA 97 (2000) 10254-10259
63. Gherardi D., D'Agati V., Chu T.H., Barnett A., Gianella-Borradori A., Gelman I.H., et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 15 (2004) 1212-1222
64. Bukanov N.O., Smith L.A., Klinger K.W., Ledbetter S.R., and Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444 (2006) 949-952
65. Rossi A.G., Sawatzky D.A., Walker A., Ward C., Sheldrake T.A., Riley N.A., et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12 (2006) 1056-1064